Update on Postnatal Corticosteroids to Prevent or Treat Bronchopulmonary Dysplasia

Abstract

Bronchopulmonary dysplasia (BPD) is a major complication of premature birth that significantly affects mortality and long-term morbidity in numerous immature infants. Corticosteroids are particularly suitable for treating BPD, as lung inflammation is central to its pathogenesis. Corticosteroids have considerable, fast beneficial effects on lung function in premature infants with lung disease, but they are also associated with several serious adverse effects, which may have a detrimental impact on long-term outcome. Dexamethasone is the most often used corticosteroid for systemic administration. Despite its value in preventing and treating BPD, its use is associated with several alarming short-term effects and, worst of all, with an increased rate of cerebral palsy in the long term. Dexamethasone nonetheless remains an important therapeutic option for infants with severe lung disease beyond the second to third week of life. Hydrocortisone is an important alternative to dexamethasone, as its use does not appear to be associated with any neurotoxic effects. Its efficacy in the prevention and treatment of BPD has yet to be clearly demonstrated, however. Inhaled corticosteroids might reduce lung inflammation with fewer systemic adverse effects; however, a recent, large randomized trial showed that inhaled budesonide was associated with an excess mortality, despite its beneficial respiratory effects. In another study, instilling budesonide together with surfactant in the trachea of intubated infants with severe respiratory distress appeared safe and achieved a significant reduction in the rate of BPD at 36 postmenstrual weeks. This important finding needs to be confirmed in a larger trial currently underway.

Keywords

preterm infant - bronchopulmonary dysplasia - postnatal corticosteroids

• References

• 1 Stoll BJ, Hansen NI, Bell EF. , et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Trends in care practices, morbidity, and mortality of extremely preterm neonates, 1993–2012. JAMA 2015; 314 (10) 1039-1051
• 2 Bonadies L, Zaramella P, Porzionato A, Muraca M, Baraldi E. Bronchopulmonary dysplasia: what's new on the horizon?. Lancet Child Adolesc Health 2018; 2 (08) 549-551
• 3 Baraldi E, Filippone M. Chronic lung disease after premature birth. N Engl J Med 2007; 357 (19) 1946-1955
• 4 Watterberg KL. ; American Academy of Pediatrics. Committee on Fetus and Newborn. Policy statement--postnatal corticosteroids to prevent or treat bronchopulmonary dysplasia. Pediatrics 2010; 126 (04) 800-808
• 5 Doyle LW, Cheong JLY. Postnatal corticosteroids to prevent or treat bronchopulmonary dysplasia - who might benefit?. Semin Fetal Neonatal Med 2017; 22 (05) 290-295
• 6 Doyle LW, Cheong JL, Ehrenkranz RA, Halliday HL. Early (< 8 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants. Cochrane Database Syst Rev 2017; 10: CD001146
• 7 Doyle LW, Cheong JL, Ehrenkranz RA, Halliday HL. Late (> 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants. Cochrane Database Syst Rev 2017; 10: CD001145
• 8 Baud O, Maury L, Lebail F. , et al; PREMILOC trial study group. Effect of early low-dose hydrocortisone on survival without bronchopulmonary dysplasia in extremely preterm infants (PREMILOC): a double-blind, placebo-controlled, multicentre, randomised trial. Lancet 2016; 387 (10030): 1827-1836
• 9 Baud O, Trousson C, Biran V, Leroy E, Mohamed D, Alberti C. ; PREMILOC Trial Group. Association between early low-dose hydrocortisone therapy in extremely preterm neonates and neurodevelopmental outcomes at 2 years of age. JAMA 2017; 317 (13) 1329-1337
• 10 Baud O, Trousson C, Biran V, Leroy E, Mohamed D, Alberti C. ; PREMILOC Trial group. Two-year neurodevelopmental outcomes of extremely preterm infants treated with early hydrocortisone: treatment effect according to gestational age at birth. Arch Dis Child Fetal Neonatal Ed 2019; 104 (01) F30-F35
• 11 Doyle LW, Halliday HL, Ehrenkranz RA, Davis PG, Sinclair JC. An update on the impact of postnatal systemic corticosteroids on mortality and cerebral palsy in preterm infants: effect modification by risk of bronchopulmonary dysplasia. J Pediatr 2014; 165 (06) 1258-1260
• 12 Onland W, Cools F, Kroon A. , et al; STOP-BPD Study Group. Effect of hydrocortisone therapy initiated 7 to 14 days after birth on mortality or bronchopulmonary dysplasia among very preterm infants receiving mechanical ventilation: a randomized clinical trial. JAMA 2019; 321 (04) 354-363
• 13 ClinicalTrialsgov. A randomized controlled trial of the effect of hydrocortisone on survival without bronchopulmonary dysplasia and on neurodevelopmental outcomes at 22–26 months of age in intubated infants <30 weeks gestation age. 2011. Available at: https://clinicaltrials.gov/ct2/show/NCT01353313?term=01353313&rank=1 . Accessed May 22, 2019
• 14 Shah VS, Ohlsson A, Halliday HL, Dunn M. Early administration of inhaled corticosteroids for preventing chronic lung disease in very low birth weight preterm neonates. Cochrane Database Syst Rev 2017; 1: CD001969
• 15 Onland W, Offringa M, van Kaam A. Late (≥ 7 days) inhalation corticosteroids to reduce bronchopulmonary dysplasia in preterm infants. Cochrane Database Syst Rev 2017; 8: CD002311
• 16 Bassler D, Plavka R, Shinwell ES. , et al; NEUROSIS Trial Group. Early inhaled budesonide for the prevention of bronchopulmonary dysplasia. N Engl J Med 2015; 373 (16) 1497-1506
• 17 Bassler D, Shinwell ES, Hallman M. , et al; Neonatal European Study of Inhaled Steroids Trial Group. Long-term effects of inhaled budesonide for bronchopulmonary dysplasia. N Engl J Med 2018; 378 (02) 148-157
• 18 Yeh TF, Chen CM, Wu SY. , et al. Intratracheal administration of budesonide/surfactant to prevent bronchopulmonary dysplasia. Am J Respir Crit Care Med 2016; 193 (01) 86-95
• 19 ClinicalTrialsgov. Intratracheal budesonide/surfactant prevents BPD. Available at: https://clinicaltrials.gov/ct2/show/NCT03275415?term=NCT03275415&rank=1 . Accessed May 22, 2019